A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
REGULATORY
Clinical Research Bill Passes Lower House
A bill for the legal regulation of clinical research was unanimously approved by the House of Representatives, the lower house of the Diet, at a plenary meeting on March 23. The bill is now up for discussion by the Upper…
To read the full story
Related Article
- Clinical Research Law Promulgated
April 17, 2017
- Clinical Research Bill Passed into Law
April 7, 2017
- Clinical Research Bill Clears Lower House Health Panel
March 21, 2017
- Clinical Research Bill Unlikely to Clear Extra Diet
December 5, 2016
- Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
September 27, 2016
- Clinical Research Bill Didn’t Clear Diet, Now under Continued Review
June 2, 2016
- Clinical Research Bill Unlikely to Clear Diet in Current Session
May 27, 2016
- Clinical Research Bill to Enter Diet Deliberations on May 20, Might Be Enacted June 1
May 19, 2016
- Clinical Research Bill OK’ed by Cabinet, Now Up for Diet Deliberations
May 13, 2016
- In a Flip-Flop, LDP Aims to Enact Clinical Research Bill in Current Diet Session
April 28, 2016
REGULATORY
- LDP Kampo Caucus Chief Wary of Removing Insurance Coverage
November 10, 2025
- LDP Panel Backs Support for Drug Wholesalers in Economic Package
November 10, 2025
- Downstream Providers Decry Growing Negative Margins at Ryukaikon
November 10, 2025
- Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
November 10, 2025
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…